Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil

OBJECTIVE: Clinical trials have shown that nintedanib 150 mg twice daily (bid) reduces disease progression in patients with idiopathic pulmonary fibrosis (IPF), with an adverse event profile that is manageable for most patients. Prior to the approval of nintedanib as a treatment for IPF in Brazil, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Pereira, Carlos Alberto de Castro, Baddini-Martinez, José Antonio, Baldi, Bruno Guedes, Jezler, Sérgio Fernandes de Oliveira, Rubin, Adalberto Sperb, Alves, Rogerio Lopes Rufino, Zonzin, Gilmar Alves, Quaresma, Manuel, Trampisch, Matthias, Rabahi, Marcelo Fouad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Pneumologia e Tisiologia 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653976/
https://www.ncbi.nlm.nih.gov/pubmed/31531619
http://dx.doi.org/10.1590/1806-3713/e20180414

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653976/
https://www.ncbi.nlm.nih.gov/pubmed/31531619
http://dx.doi.org/10.1590/1806-3713/e20180414

Ejemplares similares